Sepsis remains an increasingly complex disease with vastly different outcome rates globally. It can be healthcare-associated and is often multi-drug resistant. Sepsis kills over 8000 Australians each year and accounts for one in four ICU deaths.
Current diagnostic approaches are inadequate in a context where time is critical. In this seminar series, leading researchers will present the latest data and interpretations from recent studies and treatment interventions including diagnostic considerations, use of steroids, combination antimicrobial therapy, and nebulised antimicrobials.
The role of optimised dosing and the latest evidence regarding antimicrobial drug monitoring in sepsis will be discussed.
Learning objectives
- Diagnostic considerations for sepsis
- Role of steroids in sepsis
- Role of combination antimicrobial therapy in sepsis
- Role of nebulised antimicrobials in ventilator related pneumonia
- Role of optimised antimicrobial dosing
- Latest evidence relating to antimicrobial drug monitoring
Optimisation of Antimicrobials
We will also address the pharmacokinetic considerations in this special patient population, covering optimisation of antimicrobials for the treatment of sepsis, and the role of therapeutic drug monitoring.
To receive updates subscribe to CRE RESPOND here.
